Notice of Proposed Sale · 144
Waters Corp
WATNYSEEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- WATERS CORP /DE/
- Issuer CIK
- 0001000697
- SEC file number
- 001-14010
- Phone
- 5084782000
- Person for whose account securities are to be sold
- KUEBLER CHRISTOPHER A
- Relationships to issuer
- Director
- Street
- 34 MAPLE ST
- City
- MILFORD
- State / country code
- MA
- Postal code
- 01757
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 3,626 | 1,442,930.44 | 98,185,855 | 08/06/2026 | NYSE | Fidelity Brokerage Services LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- Fidelity Brokerage Services LLC
- Street
- 900 Salem Street
- City
- Smithfield
- State / country code
- RI
- Postal code
- 02917
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 08/06/2026 | Stock Option Exercise | Issuer | 3,626 | N | 08/06/2026 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/06/2026
- Signed
- /s/ Tyler Johnson, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Christopher A. Kuebler
Company context
Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~15,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide.
Current securities
Recent company filings
- 10-Q filingNov 10, 2026
- Results of Operations and Financial ConditionNov 3, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsAug 21, 2026
- 10-Q filingAug 11, 2026
- Results of Operations and Financial ConditionAug 4, 2026